3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
3
Thoracic
1
Sarcoma
1
Conditions
Sarcoma
16
Ovarian Neoplasms
8
Hemangiosarcoma
7
Endometrial Neoplasms
7
Carcinosarcoma
7
Breast Neoplasms
6
Sarcoma, Kaposi
4
Neoplasms
4
Melanoma
4
Lymphoma, Non-Hodgkin
4
Central Nervous System Neoplasms
4
Brain Neoplasms
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Medulloblastoma
3
Lymphoma, Mantle-Cell
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma, Follicular
3
Lymphoma, B-Cell, Marginal Zone
3
Lymphoma
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Hodgkin Disease
3
Gliosarcoma
3
Glioma
3
Glioblastoma
3
Gastrointestinal Stromal Tumors
3
Fallopian Tube Neoplasms
3
Carcinoma, Renal Cell
3
Interventions
Standard of Care
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
sarilumab
1
regorafenib
1
pexidartinib
1
pertuzumab
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
durvalumab
1
dostarlimab
1
cemiplimab
1
abemaciclib
1
Trastuzumab
1
Transurethral Resection of Bladder
1
STA 9090
1
SGN-LIV1A
1
Paclitaxel
1
MK 2206
1
Letrozole
1
Lasofoxifene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pathologic Complete Response
×
Paclitaxel
×
Sarcoma
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled